In vivo CAR T cell engineering: design principles and open questions - PubMed
5 hours ago
- #in vivo CAR T engineering
- #gene therapy
- #cancer immunotherapy
- CAR T cell therapy has significantly advanced hematologic malignancy treatment, with seven FDA-approved products.
- Widespread adoption is limited by high costs and complex manufacturing and administration processes.
- In vivo methods to directly reprogram T cells within patients aim to improve potency, reduce costs, and increase accessibility.
- Early clinical studies show safety and therapeutic potential, but questions remain about long-term efficacy and optimal disease indications.
- This review covers viral and nonviral approaches, their opportunities, limitations, and key unresolved questions in the field.